


Open Access to DEL For Data Sharing

DNA-Encoded Library (DEL) technology involves a novel affinity selection process that integrates chemistry, biology, bioinformatics and computational chemistry to facilitate a rapid drug discovery process, allowing access to more chemical space with lower cost.



In contrast to high throughput screening, DEL requires a very small amount of target protein and minimum assay development. More importantly, it disrupts the concept of “cost-per-well” and allows testing billions of compounds in one tube.

About DELopen


DELopen platform is dedicated to the development and application of DEL technology in drug discovery, initiated by WuXi AppTec in conjunction with leading academic researchers.



“ *With the support provided in this partnership we aim to bridge academia and industry and jointly promote the application of DEL technology in the field of new drug discovery.* ”


—Richard Lerner, M.D.(1938-2021)
Inventor of DEL technology & President of Scripps Research from 1987 to 2012

DELopen encourages an open, community-based approach to data sharing and exploration of the capabilities of DEL technology. We envision that DELopen will help academia benefits from the efficiency of DEL and unlock the full potential of this exciting technology.



About WuXi AppTec HitS

WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. As an innovation-driven and customer-focused unit, WuXi AppTec HitS helps our partners improve the productivity of advancing hit discovery through high-quality and cost-effective solutions.



With industry-leading capabilities such as protein science, biophysics, DNA-encoded library technology, and structural biology, WuXi AppTec HitS is committed to drive toward the realization of the vision that "every drug can be made and every disease can be treated".



**One-stop solution,
customizable**

**41+
Billion**

Target exclusivity
For all drug developers
Access to unique scaffolds



Unprecedented data release

**10.8
Billion**

Target confidentiality
For all drug developers
Easy access with reduced risk



**Free access to DEL,
data sharing**

**4.2
Billion**

Target confidentiality
For academic users
Open source

HitS Website: <https://hits.wuxiapptec.com>

Contact Us: DEL_service@wuxiapptec.com

North America: Declan Ryan declan.ryan@wuxiapptec.com

Europe: Dave Madge dave_madge@wuxiapptec.com



Our Vision

"Every drug can be made and every disease can be treated."